# Chemopreventive effects of mesalazine in patients at high risk of recurrent (nonfamilial) colorectal adenomas

Published: 19-08-2011 Last updated: 29-04-2024

1) Identify chemopreventive properties of mesalazine in patients at high risk of recurrent (nonfamilial) colorectal adenomas by evaluating the effect of treatment on apoptosis and proliferation in histologically normal sigmoid and rectal mucosa...

Ethical review Approved WMO

**Status** Recruitment stopped

**Health condition type** Benign neoplasms gastrointestinal

Study type Interventional

## **Summary**

#### ID

NL-OMON38274

#### Source

**ToetsingOnline** 

#### **Brief title**

mesalazine effects in sporadic colorectal adenoma patients

#### **Condition**

- Benign neoplasms gastrointestinal
- Gastrointestinal neoplasms benign

#### **Synonym**

sporadic colorectal adenoma, sporadic colorectal adenomatous polyps

#### Research involving

Human

## **Sponsors and support**

**Primary sponsor:** Universitair Medisch Centrum Utrecht

Source(s) of monetary or material Support: Dr. Falk Pharma Benelux B.V.

1 - Chemopreventive effects of mesalazine in patients at high risk of recurrent (non ... 2-05-2025

#### Intervention

**Keyword:** anti-proliferative, chemoprevention, pro-apoptotic, sporadic colorectal adenomatous polyp

#### **Outcome measures**

#### **Primary outcome**

The effect of treatment with mesalazine on apoptotic and proliferation indices and distribution of proliferating cells relative to the placebo group.

#### **Secondary outcome**

The effect of treatment with mesalazine on the mRNA and protein expression of  $\beta$ catenin signalling pathway components relative to the placebo group.

# **Study description**

#### **Background summary**

Patients with sporadic colorectal adenomatous polyps removed by polypectomy have a high rate of polyp recurrence and carry an increased risk for the development of colorectal carcinoma (CRC). Chemoprevention may lower the rate of adenoma recurrence after polypectomy, thereby reducing the risk of CRC development. Unlike NSAIDs mesalazine is an attractive candidate for chemoprevention, since even during long-term use it has only limited systemic adverse effects and no gastrointestinal toxicity. In a prospective trial a trend towards reduced adenoma recurrence has been observed in high risk patients with a history of at least 3 sporadic colorectal adenomas treated with mesalazine. Identification of biologically relevant antineoplastic properties of mesalazine in patients with sporadic adenomatous polyps will support further investigation of mesalazine as chemopreventive agent against colorectal neoplasia in the sporadic setting. Growth inhibition of colonic epithelial cells through induction of apoptosis and inhibition of proliferation is widely recognized as a potential mechanism for chemoprevention of colorectal cancer. In vivo data suggest that mesalazine exerts pro-apoptotic and anti-proliferative effects on normal colorectal epithelial cells. Furthermore, there is in vitro evidence in CRC cells that mesalazine inhibits Wnt/β-catenin signalling, an early and common inappropriately activated pathway in colorectal carcinogenesis and molecular target for chemoprevention.

#### Study objective

- 1) Identify chemopreventive properties of mesalazine in patients at high risk of recurrent (nonfamilial) colorectal adenomas by evaluating the effect of treatment on apoptosis and proliferation in histologically normal sigmoid and rectal mucosa relative to the placebo group.
- 2) Identify chemopreventive properties of mesalazine in patients at high risk of recurrent (nonfamilial) colorectal adenomas by evaluating the effect of treatment on expression of beta-catenin signalling pathway components in histologically normal sigmoid and rectal mucosa relative to the placebo group.

#### Study design

double-blind, randomized placebo-controlled study

#### Intervention

Treatment with 3.0 g mesalazine or placebo once daily for 6 months. At baseline and after 6 months of treatment, a sigmoidoscopy will be performed and biopsies of normal appearing sigmoid and rectal mucosa will be collected.

#### Study burden and risks

Very rarely renal and liver disorders occur as a result from using mesalazine. In general these resolve after the use of mesalazine is discontinued. Four times during the study period blood samples will be drawn to check renal and liver function.

Five additional hospital visits are required for this study; one for screening and informed consent, twice to undergo a sigmoidoscopy and twice for adverse effects evaluation and compliance monitoring. During four of these visits a questionnaire concerning use of concomitant medication and nutritional supplements has to be completed.

A sigmoidoscopy is in general a safe examination with rarely complications occuring. Risk increase due to biopsy taking is negligible.

## **Contacts**

#### **Public**

Universitair Medisch Centrum Utrecht

Heidelberglaan 100 Utrecht 3584 CX NL

#### **Scientific**

3 - Chemopreventive effects of mesalazine in patients at high risk of recurrent (non ... 2-05-2025

Universitair Medisch Centrum Utrecht

Heidelberglaan 100 Utrecht 3584 CX NL

## **Trial sites**

#### **Listed location countries**

Netherlands

# **Eligibility criteria**

#### Age

Adults (18-64 years) Elderly (65 years and older)

#### Inclusion criteria

- Within 6 months before study entry having undergone complete colonoscopy with polypectomy for removal of sporadic adenomatous polyps. This should be 2 or more adenomas, irrespective of size, and/or one adenoma with a diameter of at least 1 cm and/or with proximal localization and/or with villous aspects or high-grade dysplasia.
- age 50-75 years

#### **Exclusion criteria**

- inflammatory bowel disease
- familial colorectal cancer syndrome
- history of colorectal carcinoma
- history of surgery to the large bowel (except appendectomy)
- chronic renal insufficiency
- chronic hepatic insufficiency
- allergy to salicylates
- asthma
- diabetes mellitus
- coagulation disorder or anticoagulant use, which cannot be temporarily discontinued
- regular intake of thiopurines, methotrexate or cyclosporin
- prescription use of aspirin (high- and low-dose) or other NSAIDs

# Study design

## **Design**

Study phase: 2

Study type: Interventional

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Double blinded (masking used)

Control: Placebo

Primary purpose: Prevention

#### Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 13-07-2012

Enrollment: 68

Type: Actual

## Medical products/devices used

Product type: Medicine

Brand name: Salofalk granules

Generic name: mesalazine

Registration: Yes - NL outside intended use

## **Ethics review**

Approved WMO

Date: 19-08-2011

Application type: First submission

Review commission: METC Universitair Medisch Centrum Utrecht (Utrecht)

Approved WMO

Date: 11-11-2011

Application type: First submission

Review commission: METC Universitair Medisch Centrum Utrecht (Utrecht)

Approved WMO

Date: 06-03-2012

Application type: Amendment

Review commission: METC Universitair Medisch Centrum Utrecht (Utrecht)

Approved WMO

Date: 12-03-2012

Application type: Amendment

Review commission: METC Universitair Medisch Centrum Utrecht (Utrecht)

Approved WMO

Date: 17-12-2012

Application type: Amendment

Review commission: METC Universitair Medisch Centrum Utrecht (Utrecht)

Approved WMO

Date: 15-01-2013

Application type: Amendment

Review commission: METC Universitair Medisch Centrum Utrecht (Utrecht)

Approved WMO

Date: 04-11-2014
Application type: Amendment

Review commission: METC Universitair Medisch Centrum Utrecht (Utrecht)

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

# Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register ID

EudraCT EUCTR2011-001815-29-NL CCMO NL36557.041.11